Press "Enter" to skip to content

Tag: Pfizer

COVID-19 boosters start rolling out to some Canadians. Who can get them?

Updated COVID-19 vaccines are starting to roll out to some high-risk Canadians, but others will have to wait a little while longer before these new shots are offered to them.

Last month, Health Canada approved Pfizer and Moderna’s latest COVID-19 vaccines targeting the most recent variants of the virus.

Both shots are approved for everyone aged six months and older.

The new mRNA vaccines from both pharmaceutical companies target the KP.2 subvariant of Omicron that was dominating COVID-19 spread earlier this year.

Comments closed

For Canadians seeking a non-mRNA COVID vaccine, lack of Novavax shot is ‘unfair,’ advocates say

The federal government’s decision to not provide Novavax’s COVID-19 vaccine this respiratory virus season raises health equity concerns, experts and advocates say, as some Canadians look to the U.S. to get the shot.

The Public Health Agency of Canada said it won’t provide the protein-based vaccine called Nuvaxovid because the manufacturer required a minimum order that far exceeds last year’s uptake of the vaccine.

The health agency said 125,000 Nuvaxovid doses were ordered in 2023, but only 5,529 were administered. This fall, it will only supply provinces and territories with the reformulated Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines.

But some Canadians who say they are immunocompromised and have had adverse reactions to the mRNA vaccines are calling the decision unfair.

Comments closed

Canadian government not ordering Novavax’s protein-based COVID-19 vaccine this year

TORONTO – The Public Health Agency of Canada says it is not providing Novavax’s COVID-19 vaccine this respiratory virus season, citing low demand.

It says the manufacturer requires a minimum order of its updated protein-based vaccine, called Nuvaxovid, which far exceeds the uptake by Canadians last year.

The agency says a very small portion of the doses ordered in 2023 were used and that its decision reflects efforts to limit vaccine wastage.

It is distributing two mRNA vaccines — made by Pfizer-BioNTech and Moderna — that are approved for adults and children six months and older.

Comments closed

Health Canada approves Pfizer-BioNTech’s updated COVID-19 vaccine

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against the most recently circulating variants of the virus.

Pfizer-BioNTech’s mRNA vaccine, called Comirnaty, targets the KP.2 subvariant of Omicron, replacing the previous version that targeted the XBB.1.5 Omicron subvariant.

The approval of Comirnaty follows last week’s authorization of Moderna’s updated Spikevax mRNA vaccine and Novavax’s updated protein-based vaccine, Nuvaxovid.

Comments closed

Moderna’s updated COVID-19 vaccine is coming to Alberta, but Novavax shots are not

With the approval of Moderna’s updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans will opt to roll up their sleeves to get one.

Last week, Health Canada announced it had authorized Moderna’s new formulation, which targets the recent KP.2 subvariant, and that shipments would arrive within days.

A decision on Pfizer’s new formulation is expected in the next few weeks.

Comments closed

FDA may greenlight updated Covid-19 vaccines as soon as next week, sources say

The US Food and Drug Administration is poised to sign off as soon as next week on updated Covid-19 vaccines targeting more recently circulating strains of the virus, according to two sources familiar with the matter, as the country experiences its largest summer wave in two years.

The agency is expected to greenlight updated mRNA vaccines from Moderna and Pfizer/BioNTech that target a strain of the virus called KP.2, said the sources, who declined to be named because the timing information isn’t public. It was unclear whether the agency simultaneously would authorize Novavax’s updated shot, which targets the JN.1 strain.

The move would be several weeks ahead of last year’s version of the vaccine, which got FDA signoff on September 11.

Comments closed

Updated COVID vaccine 71% effective against hospitalization for older adults

The estimated effectiveness of the updated COVID-19 vaccine among people aged 60 and older in the Netherlands was 70.7% against hospitalization and 73.3% against intensive care unit (ICU) admission in fall and early winter 2023, according to a study published yesterday in Eurosurveillance.

Researchers at the National Institute for Public Health and the Environment and University Medical Center Utrecht parsed data on hospitalizations with admission dates from October to December to estimate the effectiveness of the XBB.1.5 Pfizer/BioNTech COVID-19 vaccine among recipients of at least one previous vaccination. The study included 2,050 hospitalized adults aged 60 and older, 14.4% of whom had received the 2023 COVID-19 vaccine.

Comments closed

Health Canada approves RSV vaccine for maternal immunization

Health Canada has approved a new vaccine geared toward protecting two groups most severely affected by the respiratory syncytial virus (RSV): newborns, who would receive antibodies through maternal immunization, and Canadians over 60.

Pfizer Canada’s bivalent vaccine, called Abrysvo, aims to prevent lower respiratory tract disease caused by the virus.

It is the first RSV vaccine in Canada approved for use in pregnancy to provide protection for infants from birth to six months of age, and the second approved for seniors aged 60 and over.

Comments closed

Canada has ‘sufficient supply’ of new COVID-19 vaccines amid ‘pandemic amnesia,’ experts say

As doctors recommend new COVID-19 vaccine doses to combat the XBB.1.5 Omicron subvariant, a mutation of COVID-19 that has continued to spread despite misconceptions that the virus is in the past, officials say Canada has sufficient supply.

Comments closed

Pfizer more than doubles price of lifesaving Covid-19 medication Paxlovid as US transitions out of pandemic phase

The price of the lifesaving Covid-19 antiviral medication Paxlovid will more than double as the United States transitions out of the emergency phase of the pandemic, drugmaker Pfizer said Wednesday.

Comments closed

Is the Novavax COVID Vaccine Better than mRNA Vaccines? What We Know So Far

As the updated COVID vaccines roll out around the country, one more competitor has joined the mix. In early October the U.S. Food and Drug Administration authorized a new booster shot made by the company Novavax. Like the mRNA-based Pfizer and Moderna shots, it targets a SARS-CoV-2 variant, XBB.1.5, which is a descendant of Omicron.

Comments closed

Appointments for new Moderna COVID-19 vaccine now available in N.S.

Appointments are now available in Nova Scotia for a new monovalent Moderna COVID-19 vaccine, which the provincial government says provides the best protection against the latest strain of the virus.

Comments closed

Pfizer’s updated COVID vaccine approved by Health Canada

Pfizer’s updated COVID-19 vaccine for the upcoming fall and winter months has been granted Health Canada approval.

Pfizer’s updated vaccine is approved for people six months and older.

Comments closed

Health Canada authorizes updated Pfizer-BioNTech COVID vaccine

Health Canada has authorized Pfizer-BioNTech’s updated COVID-19 vaccine for people six months and older.

The mRNA vaccine targets the Omicron XBB.1.5 subvariant that is circulating in Canada.

Comments closed

US CDC recommends broad use of updated COVID‑19 vaccines

The U.S. Centers for Disease Control and Prevention director on Tuesday signed off on broad use of updated COVID-19 vaccines approved by the government – covering ages 6 months and up – as the country prepares to start a vaccination campaign within days.

Comments closed

Health Canada approves Moderna’s updated COVID-19 vaccine

Health Canada has approved Moderna’s updated COVID-19 vaccine for all Canadians who are six months of age and older — while two other options for fall shots remain in the regulatory pipeline.

Comments closed

New COVID shots effective against latest variant, Pfizer and Moderna say

Pfizer on Wednesday said the updated Pfizer-BioNTech COVID-19 vaccine expected to be used this fall elicited a strong antibody response against the highly mutated BA.2.86 subvariant of the coronavirus in a preclinical study in mice.

Comments closed

Will updated COVID vaccines work against latest variant? Canadian scientists monitor global research

Health Canada is currently reviewing applications for Moderna and Pfizer-BioNTech’s new mRNA vaccines, developed against the dominant XBB.1.5 variant ahead of a vaccination campaign set for the fall.

Comments closed